A phase III trial demonstrated that EREG expression can be a predictor for overall survival in oxaliplatin/fluoropyrimidine plus bevacizumab-treated metastatic colorectal cancer patients without RAS and BRAF mutations [33]. Here, BRAF is linked to metastatic colorectal cancer.